ArticleG3 (Bethesda, Md.)2026
Regulated proteolysis of green fluorescent protein fusion proteins in Aspergillus fumigatus.
Article in G3 (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Aspergillosis caused by Aspergillus fumigatus is a clinical issue of such severity that the World Health Organization has designated this organism as 1 of the 4 most critical fungi to study. Progress in A. fumigatus has been limited by the availability of genetic tools with which to study this filamentous fungus. Currently available means of altering the dosage of genes and gene products include construction of disruption mutants as well as regulated promoters. These are powerful techniques but somewhat limited for the analysis of essential genes. Here we describe a new method that permits regulated proteolysis of any A. fumigatus protein that can be made as a fusion protein to the well-described green fluorescent protein (GFP) of Aequorea victoria. A GFP fusion protein of interest can be targeted for degradation using a single-chain antibody called a nanobody that recognizes GFP (GFPNb). This GFPNb is in turn fused to an E3 ligase protein called Rnf4 from rat that efficiently ubiquitinates target proteins. A fusion gene was constructed under control of a doxycycline-inducible promoter that produced a GFPNb-Rnf4 fusion protein in A. fumigatus. Here, we show that production of this GFPNb-Rnf4 protein led to the rapid proteolysis of a variety of GFP fusion proteins. Additionally, we found that some GFP fusion proteins triggered a corresponding genomic response when their degradation was induced, while others were simply degraded. These studies provide a new means to directly regulate protein levels in A. fumigatus and generate new alleles of genes, exposing the underlying regulatory circuitry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.